Clinical and Translational Oncology

, Volume 9, Issue 7, pp 409–411

Intraperitoneal chemotherapy for optimally debulked advanced ovarian cancer: A new standard in patient care?

Editorial

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jemal A, Siegel R, Ward E et al (2006) Cancer Statistics, 2006. CA Cancer J Clin 56:106–130PubMedCrossRefGoogle Scholar
  2. 2.
    Bristow RE, Tomacruz RS, Armstrong DK et al (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum-era: a meta-analysis. J Clin Oncol 20:1248–1259PubMedCrossRefGoogle Scholar
  3. 3.
    McGuire WP, Hoskins WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1–6PubMedCrossRefGoogle Scholar
  4. 4.
    Piccart MJ, Bertelsen K, James K et al (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92:699–708PubMedCrossRefGoogle Scholar
  5. 5.
    Ozols RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194–3200PubMedCrossRefGoogle Scholar
  6. 6.
    du Bois A, Lück H-J, Meier W et al (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320–1330PubMedGoogle Scholar
  7. 7.
    du Bois A, Quinn M, Thigpen T et al (2005) 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 16:viii7–12PubMedCrossRefGoogle Scholar
  8. 8.
    Dedrick RL, Myers CE, Bungay PM et al (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1–9PubMedGoogle Scholar
  9. 9.
    Casper ES, Kelsen DP, Alcock NW et al (1983) IP cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the ivroute. Cancer Treat Rep 67:235–238PubMedGoogle Scholar
  10. 10.
    Francis P, Rowinsky E, Schneider J et al (1995) Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol 13:2961–2967PubMedGoogle Scholar
  11. 11.
    Alberts DS, Liu PY, Hannigan EV et al (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950–1955PubMedCrossRefGoogle Scholar
  12. 12.
    Markman M, Bundy BN, Alberts DS et al (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001–1007PubMedGoogle Scholar
  13. 13.
    Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43PubMedCrossRefGoogle Scholar
  14. 14.
    (2006) Clinical advisory: NCI issues clinical announcement for preferred method of treatment for advanced ovarian cancer. Available on WWW at www.nlm.nih.gov/databases/alerts/ovarian_ip_chemo.htmlGoogle Scholar
  15. 15.
    Markman M, Walker JL (2006) Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol 24:988–993PubMedCrossRefGoogle Scholar
  16. 16.
    Wenzel LB, Huang HQ, Armstrong DK et al (2007) Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 25:437–443PubMedCrossRefGoogle Scholar
  17. 17.
    Walker JL, Armstrong DK, Huang HQ et al (2006) Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 100:27–32PubMedCrossRefGoogle Scholar
  18. 18.
    Ozols RF, Bookman MA, Young RC et al (2006) Intraperitoneal cisplatin therapy in ovarian cancer: Comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol 103:1–6PubMedCrossRefGoogle Scholar
  19. 19.
    Gore M, du Bois A, Vergote I (2006) Intraperitoneal chemotherapy in ovarian cancer remains experimental. J Clin Oncol 24:4528–4530PubMedCrossRefGoogle Scholar

Copyright information

© Feseo 2007

Authors and Affiliations

  1. 1.Servicio Oncología MédicaHospital Universitario Ramón y CajalMadridSpain

Personalised recommendations